179 related articles for article (PubMed ID: 33363651)
1. THE EXPRESSION OF STEM CELL MARKERS (CD133, NESTIN, OCT4, SOX2) IN INVASIVE PITUITARY ADENOMAS.
Basaran R; Gundogan D; Senol M; Bozdogan C; Gezen F; Sav A
Acta Endocrinol (Buchar); 2020; 16(3):303-310. PubMed ID: 33363651
[TBL] [Abstract][Full Text] [Related]
2. Identification of CD133+ cells in pituitary adenomas.
Yunoue S; Arita K; Kawano H; Uchida H; Tokimura H; Hirano H
Neuroendocrinology; 2011; 94(4):302-12. PubMed ID: 21912092
[TBL] [Abstract][Full Text] [Related]
3. Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas.
Würth R; Barbieri F; Pattarozzi A; Gaudenzi G; Gatto F; Fiaschi P; Ravetti JL; Zona G; Daga A; Persani L; Ferone D; Vitale G; Florio T
Mol Neurobiol; 2017 Sep; 54(7):4879-4895. PubMed ID: 27514754
[TBL] [Abstract][Full Text] [Related]
4. Identification and gene expression profiling of human gonadotrophic pituitary adenoma stem cells.
Yuan L; Li P; Li J; Peng J; Zhouwen J; Ma S; Jia G; Jia W; Kang P
Acta Neuropathol Commun; 2023 Feb; 11(1):24. PubMed ID: 36750863
[TBL] [Abstract][Full Text] [Related]
5. Pituitary tumours without distinct lineage differentiation express stem cell marker SOX2.
Lenders NF; Thompson TJ; Chui J; Low J; Inder WJ; Earls PE; McCormack AI
Pituitary; 2024 Jun; 27(3):248-258. PubMed ID: 38483762
[TBL] [Abstract][Full Text] [Related]
6. [LincRNA-ROR functions as a ceRNA to regulate Oct4, Sox2, and Nanog expression by sponging miR-145 and its effect on biologic characteristics of colonic cancer stem cells].
Yan ZY; Sun XC
Zhonghua Bing Li Xue Za Zhi; 2018 Apr; 47(4):284-290. PubMed ID: 29690669
[No Abstract] [Full Text] [Related]
7. SOX 2 Expression in Human Pituitary Adenomas-Correlations With Pituitary Function.
Capatina C; Cimpean AM; Raica M; Coculescu M; Poiana C
In Vivo; 2019; 33(1):79-83. PubMed ID: 30587606
[TBL] [Abstract][Full Text] [Related]
8. Elevated soluble epidermal growth factor receptor level in pituitary adenoma and carcinoma.
Kong YG; Ren ZY; Su CB; Wang RZ; Ma WB; Lian W
Chin Med Sci J; 2004 Sep; 19(3):199-202. PubMed ID: 15506648
[TBL] [Abstract][Full Text] [Related]
9. Differences in stem cell marker and osteopontin expression in primary and recurrent glioblastoma.
Polat B; Wohlleben G; Kosmala R; Lisowski D; Mantel F; Lewitzki V; Löhr M; Blum R; Herud P; Flentje M; Monoranu CM
Cancer Cell Int; 2022 Feb; 22(1):87. PubMed ID: 35183162
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Utility of TIMP3 Expression in ACTH-Secreting Pituitary Tumor.
Sun B; Liu X; Yang Y; Dai C; Li Y; Jiao Y; Wei Z; Yao Y; Feng M; Bao X; Deng K; Wang N; Wang R
J Mol Neurosci; 2016 Jan; 58(1):137-44. PubMed ID: 26676407
[TBL] [Abstract][Full Text] [Related]
11. Expression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas.
Gao Z; Cai L; Lu J; Wang C; Li Q; Chen J; Song X; Chen X; Zhang L; Zheng W; Su Z
Med Sci Monit; 2017 Apr; 23():1827-1833. PubMed ID: 28411401
[TBL] [Abstract][Full Text] [Related]
12. Endocrinological outcome following first time transsphenoidal surgery for GH-, ACTH-, and PRL-secreting pituitary adenomas.
Kristof RA; Schramm J; Redel L; Neuloh G; Wichers M; Klingmüller D
Acta Neurochir (Wien); 2002 Jun; 144(6):555-61; discussion 561. PubMed ID: 12111488
[TBL] [Abstract][Full Text] [Related]
13. Pit-1 gene expression in human pituitary adenomas using the reverse transcription polymerase chain reaction method.
Yamada S; Takahashi M; Hara M; Hattori A; Sano T; Ozawa Y; Shishiba Y; Hirata K; Usui M
Clin Endocrinol (Oxf); 1996 Sep; 45(3):263-72. PubMed ID: 8949563
[TBL] [Abstract][Full Text] [Related]
14. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
Korbonits M; Jacobs RA; Aylwin SJ; Burrin JM; Dahia PL; Monson JP; Honegger J; Fahlbush R; Trainer PJ; Chew SL; Besser GM; Grossman AB
J Clin Endocrinol Metab; 1998 Oct; 83(10):3624-30. PubMed ID: 9768675
[TBL] [Abstract][Full Text] [Related]
15. Embryonic stem cells markers SOX2, OCT4 and Nanog expression and their correlations with epithelial-mesenchymal transition in nasopharyngeal carcinoma.
Luo W; Li S; Peng B; Ye Y; Deng X; Yao K
PLoS One; 2013; 8(2):e56324. PubMed ID: 23424657
[TBL] [Abstract][Full Text] [Related]
16. Significance of leptin expression in invasive potential of pituitary adenomas.
Isono M; Inoue R; Kamida T; Kobayashi H; Matsuyama J
Clin Neurol Neurosurg; 2003 Apr; 105(2):111-6. PubMed ID: 12691803
[TBL] [Abstract][Full Text] [Related]
17. Early recognition of aggressive pituitary adenomas: a single-centre experience.
Ceccato F; Regazzo D; Barbot M; Denaro L; Emanuelli E; Borsetto D; Rolma G; Alessio L; Gardiman MP; Lombardi G; Albiger N; D'Avella D; Scaroni C
Acta Neurochir (Wien); 2018 Jan; 160(1):49-55. PubMed ID: 29170844
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and treatment of pituitary adenomas.
Chanson P; Salenave S
Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
[TBL] [Abstract][Full Text] [Related]
19. Clinical Relevance and Immunohistochemical Patterns of Silent Pituitary Adenomas: 10 Years of Single-centre Experience.
Akkus G; Karagun B; Çetinalp NE; Açıkalın A; Evran M; Sengöz S; Sert M; Zorludemir S; Tetiker T
Curr Med Imaging; 2021; 17(2):310-317. PubMed ID: 33357196
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of Pit-1 protein in human pituitary adenomas.
Inada K; Oda K; Utsunomiya H; Sanno N; Itoh J; Osamura RY; Voss JW; Rosenfeld MG
Endocr Pathol; 1993 Dec; 4(4):201-204. PubMed ID: 32138434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
